People · Operator
Named in public records as an officer, director or promoter · active 2015–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. | — | Biotechnology | Series C | $178.6M | $433.3M | 2015 |
| Angarus Therapeutics, Inc. | — | Biotechnology | Series A | $11.3M | $328.8M | 2020 |
Chih-Ping Liu at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Chih-Ping Liu on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Healy | 1 | 8 |
| Richard Miller | 1 | 8 |
| Peter Moldt | 1 | 6 |
| Mahendra Shah | 1 | 5 |
| Edgar G Engleman | 1 | 5 |
| Ashish Khanna | 1 | 3 |
| Mahendra G. Shah | 1 | 3 |
| Ashish G. Khanna | 1 | 2 |
| Reiner Laus | 1 | 2 |
| Kathleen LaPorte | 1 | 2 |
| Randall Schatzman | 1 | 2 |
| William Quinn | 1 | 2 |
| David Dornan | 1 | 2 |
| Edith Perez | 1 | 1 |
| Grant Yonehiro | 1 | 1 |
| Grant G. Yonehiro | 1 | 1 |
| Ken G. Harrison | 1 | 1 |
| Peter G. Moldt | 1 | 1 |
| Peter G. Bisgaard | 1 | 1 |
| Nigel Ray | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.